



Balfour Capital Group Viking Therapeutics, Inc.

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders. Their lead candidate, VK2735, is a dual agonist targeting GLP-1 and GIP receptors, currently in Phase 2 trials for obesity. Another candidate, VK2809, is being evaluated for non-alcoholic steatohepatitis (NASH) and fibrosis.

1. Top 5 Competitors

Viking Therapeutics operates in a competitive landscape with several companies developing treatments for metabolic and endocrine disorders. Notable competitors include:

1. Novo Nordisk
2. Eli Lilly
3. Madrigal Pharmaceuticals
4. Apellis Pharmaceuticals
5. Scholar Rock Holding

These companies are engaged in developing therapies that may compete with Viking's pipeline candidates.

2. Largest Institutional Shareholders

As of the latest filings, the top institutional shareholders in Viking Therapeutics include:

- FMR LLC: \$672.63 million
- State Street Corp: \$295.92 million
- Avoro Capital Advisors LLC: \$294.38 million
- Vanguard Group Inc.: \$245.47 million
- Perpetual Ltd: \$80.35 million

Institutional investors control approximately 73% of Viking Therapeutics' shares.

3. Management Team

- Brian Lian, Ph.D. – President, CEO & Director
- Greg Zante – Chief Financial Officer
- Marianne Mancini – Chief Operating Officer
- Lawson Macartney, DVM, Ph.D. – Chairman of the Board



Balfour Capital Group Viking Therapeutics, Inc.

4. Revenue

Viking Therapeutics is currently in the clinical stage and does not have commercial products on the market, resulting in minimal revenue. For the first quarter of 2025, the company reported a net loss of \$45.6 million, or \$0.41 per share.

5. Institutions with Buy Recommendations:

Several institutions have issued buy recommendations for Viking Therapeutics:

- Jefferies: Initiated coverage with a Buy rating.
- William Blair: Maintains an Outperform rating.
- Raymond James: Positive outlook on recent developments.

6. Analyst Sentiment Summary

Analyst sentiment toward Viking Therapeutics is predominantly positive:

- Average Recommendation: Buy
- Average Target Price: \$90.26
- Number of Ratings: 19

In the current month, Viking Therapeutics has received 35 Buy ratings, 1 Hold rating, and 0 Sell ratings.

7. Insider Buying and Selling (Last 24 Months)

Over the past 24 months, insider transactions include:

- Purchases:
 - Sarah Kathryn Rouan (Director) purchased 1,240 shares at \$24.15 per share.
- Sales:
 - Brian Lian (President & CEO) sold multiple tranches totaling over 400,000 shares.
 - Greg Zante (CFO) sold approximately 198,443 shares.
 - Marianne Mancini (COO) sold 281,425 shares.